Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 2101 McGavran-Greenberg Hall, Chapel Hill, NC, 27599, USA.
Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, USA.
AIDS Behav. 2019 Mar;23(3):592-601. doi: 10.1007/s10461-018-2282-3.
Little is known about disparities in depression prevalence, treatment, and remission by psychiatric comorbidities and substance use among persons living with HIV (PLWH). We conducted a cross-sectional analysis in a large cohort of PLWH in routine care and analyzed conditional probabilities of having an indication for depression treatment, receiving treatment, receiving indicated treatment adjustments, and achieving remission, stratified by alcohol use, illicit drug use, and panic symptoms. Overall, 34.7% (95% CI 33.9-35.5%) of participants had an indication for depression treatment and of these, 55.3% (53.8-56.8%) were receiving antidepressants. Among patients receiving antidepressants, 33.0% (31.1-34.9%) had evidence of remitted depression. In a subsample of sites with antidepressant dosage data, only 8.8% (6.7-11.5%) of patients received an indicated treatment adjustment. Current drug users (45.8%, 95% CI 43.6-48.1%) and patients reporting full symptoms of panic disorder (75.0%, 95% CI 72.9-77.1%) were most likely to have an indication for antidepressant treatment, least likely to receive treatment given an indication (current drug use: 47.6%, 95% CI 44.3-51.0%; full panic symptoms: 50.8%, 95% CI 48.0-53.6%), or have evidence of remitted depression when treated (22.3%, 95% CI 18.5-26.6%; and 7.3%, 95% CI 5.5-9.6%, respectively). In a multivariable model, drug use and panic symptoms were independently associated with poorer outcomes along the depression treatment cascade. Few differences were evident by alcohol use. Current drug users were most likely to have an indication for depression treatment, but were least likely to be receiving treatment or to have remitted depression. These same disparities were even more starkly evident among patients with co-occurring symptoms of panic disorder compared to those without. Achieving improvements in the depression treatment cascade will likely require attention to substance use and psychiatric comorbidities.
目前对于精神共病和物质使用对 HIV 感染者(PLWH)的抑郁患病率、治疗和缓解率的差异知之甚少。我们对常规护理中的大量 PLWH 进行了一项横断面分析,并按酒精使用、非法药物使用和惊恐症状对有抑郁治疗指征、接受治疗、接受有指征的治疗调整和达到缓解的可能性进行了分层分析。总体而言,34.7%(95%CI 33.9-35.5%)的参与者有抑郁治疗指征,其中 55.3%(53.8-56.8%)接受了抗抑郁药治疗。在接受抗抑郁药治疗的患者中,33.0%(31.1-34.9%)有缓解抑郁的证据。在有抗抑郁药剂量数据的亚组中,只有 8.8%(6.7-11.5%)的患者接受了有指征的治疗调整。目前的药物使用者(45.8%,95%CI 43.6-48.1%)和报告有惊恐障碍全部症状的患者(75.0%,95%CI 72.9-77.1%)最有可能有抗抑郁药治疗的指征,最不可能在有指征的情况下接受治疗(目前的药物使用者:47.6%,95%CI 44.3-51.0%;有惊恐障碍全部症状的患者:50.8%,95%CI 48.0-53.6%),或在接受治疗时有缓解抑郁的证据(22.3%,95%CI 18.5-26.6%;和 7.3%,95%CI 5.5-9.6%)。在多变量模型中,药物使用和惊恐症状与抑郁治疗级联中的较差结果独立相关。酒精使用的差异并不明显。目前的药物使用者最有可能有抑郁治疗的指征,但最不可能接受治疗或缓解抑郁。与没有共病惊恐障碍的患者相比,这些同样的差异在同时患有惊恐障碍症状的患者中更为明显。要改善抑郁治疗级联,可能需要关注物质使用和精神共病。